Skip to main content

Table 1 Clinical features and details of patients receiving intravenous PMB

From: Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study

Characteristic Mean ± SD, or n (%)
Age (year) 55.91 ± 17.14
Male (%) 79 (79)
ICU admission, n (%) 98 (98)
Mechanical ventilation, n (%) 49 (49)
Chronic medical conditions, n (%)
 Heart disease 14 (14)
 Hypertension 44 (44)
 Stroke 19 (19)
 Cancer 6 (6)
 Diabetes mellitus 15 (15)
 Chronic obstructive pulmonary disease 1 (1)
Renal insufficiency, n (%) 27 (27)
Septic shock, n (%) 39 (39)
SOFA score, mean ± SD 7.76 ± 4.30
APACHE II, mean ± SD 17.61 ± 7.59
ICU stay before intravenous PMB, days, median (IQR) 8 (3, 14)
MODS, n (%) 60 (60)
PCT, ng/ml, median (IQR) 3.89 (1.08, 11.43)
Bacterial, n (%)
 AB 33 (33)
 KP 48 (48)
 PA 16 (16)
 Other 9 (9)
 Unknown 15 (15)
Infection sites, n (%)
 BSI 40 (40)
 Pulmonary infection 64 (64)
 Intraperitoneal infection 9 (9)
 Incision infection 6 (6)
 Others 18 (18)
Concomitant antibiotic therapy
 PMB + Carbapenem 30 (30)
 PMB + Carbapenem + Tigecycline 26 (26)
 PMB + Tigecycline 11 (11)
 PMB + Cephalosporin 9 (9)
 PMB + Carbapenem + Cephalosporin 8 (8)
 Others 16 (16)
Daily dose of PMB, mg/day, n (%)
 100 53 (53)
 150 17 (17)
 200 30 (30)
  1. PMB: polymyxin B; ICU: intensive care unit; SOFA: Sequential Organ Failure Assessment; APACHE II: Acute Physiology and Chronic Health Evaluation II; MODS: multiple organ dysfunction syndrome; PCT: procalcitonin; KP: Klebsiella pneumoniae, AB: Acinetobacter baumannii; PA: Pseudomonas aeruginosa; BSI: bloodstream infection